ORIGINAL ARTICLE

A third MRX family (MRX68) is the result of mutation in the long chain fatty acid-CoA ligase 4 (*FACL4*) gene: proposal of a rapid enzymatic assay for screening mentally retarded patients

I Longo, S G M Frints, J-P Fryns, I Meloni, C Pescucci, F Ariani, M Borghgraef, M Raynaud, P Marynen, C Schwartz, A Renieri, G Froyen

J Med Genet 2003;40:11–17

See end of article for authors' affiliations

Correspondence to:
Dr A Renieri, Medical
Genetics, University of
Siena, Policlinico Le Scotte,
Viale Bracci 2, 53100
Siena, Italy; renieri@unisi.it

Revised version received
18 September 2002
Accepted for publication
18 September 2002

Background: The gene encoding fatty acid CoA ligase 4 (*FACL4*) is mutated in families with non-specific X linked mental retardation (MRX) and is responsible for cognitive impairment in the contiguous gene syndrome ATS-MR (Alport syndrome and mental retardation), mapped to Xq22.3. This finding makes this gene a good candidate for other mental retardation disorders mapping in this region.

Methods: We have screened the *FACL4* gene in eight families, two MRX and six syndromic X linked mental retardation (MRXS), mapping in a large interval encompassing Xq22.3.

Results: We have found a missense mutation in MRX68. The mutation (c.1001C>T in the brain isoform) cosegregates with the disease and changes a highly conserved proline into a leucine (p.P375L) in the first luciferase domain, which markedly reduces the enzymatic activity. Furthermore, all heterozygous females showed completely skewed X inactivation in blood leucocytes, as happens in all reported females with other *FACL4* point mutations or deletions.

Conclusions: Since the *FACL4* gene is highly expressed in brain, where it encodes a brain specific isoform, and is located in hippocampal and cerebellar neurones, a role for this gene in cognitive processes can be expected. Here we report the third MRX family with a *FACL4* mutation and describe the development of a rapid enzymatic assay on peripheral blood that we propose as a sensitive, robust, and efficient diagnostic tool in mentally retarded males.

Mental retardation is a condition characterised by significantly below average intellectual functioning (IQ < 70) in conjunction with significant limitations in adaptive functioning, occurring before the age of 18 years.¹ An excess of males in mentally retarded patients has long been noticed and explained by the presence of mutations in one gene on the X chromosome.² It is calculated that X linked mental retardation (XLMR) may account for about 20–25% of mentally retarded males.^{3–5} Usually, XLMR is divided into “syndromic” (MRXS) and “non-specific” (MRX) forms, depending on the presence or absence, besides mental retardation, of a specific pattern of physical, neurological, or metabolic abnormalities. Up to now, 11 genes have been found to be involved in MRX. This number of genes may rise to more than 100 since the mutation frequency of the identified genes is very low (0.01–1%) and no major MRX gene seems to exist.⁶ For several of the reported genes, knowledge of the pathogenesis is very limited and apparently they do not seem to participate in a common pathway: *FMR2* on Xq28 encodes a nuclear protein that may be a transcriptional regulator^{7,8}; *GDII*, on Xq28, is implicated in synaptic vesicle cycling and neurotransmitter release⁹; *TMA5F2* (alias *MXS1*), on Xp11.4, interacts with beta-1 integrins and may have a role in the control of neurite outgrowth¹⁰; *IL1RAPL1*, on Xp22.1–Xp21.3, is related to interleukin-1 receptor accessory proteins.¹¹ Three genes, the oligophrenin-1 gene (*OPHN1*) on Xq12, *PAK3* on Xq21.3–q24, and *ARHGEF* on Xq26, encode proteins involved in the Rho GTPases pathways.^{12–15} These signal transduction pathways are thought to mediate organisation of the cytoskeleton, cell shape, and motility, and may be responsible for axonal outgrowth and the shape and size of dendrites. Three genes, *RPS6KA3* (*RSK2*) on Xp22, *MECP2* on Xq28, and *ARX* on

Xp21.3–22.1, are associated with both MRX and MRXS (Coffin-Lowry, Rett, X linked West, and Partington syndromes). These three genes may be involved in a common pathway of gene expression regulation and chromatin remodelling, indicating that the disruption of another cellular process, beside the Rho-GTPases cycle, may lead to MR.^{16–17–18–19}

The human long chain fatty acyl-CoA ligase (or synthetase) 4 (*FACL4* or (*L*)*ACS4*) gene on Xq22.3 may be involved in a new MR pathogenic pathway owing to alteration of lipid metabolism.²⁰ We first reported that this gene is included in a large genomic deletion leading to a contiguous gene syndrome characterised by Alport syndrome, mental retardation, mid-face hypoplasia, and elliptocytosis (AMME, OMIM 300194).^{21–22} Subsequently, we showed that the same gene is also deleted in a second family with a smaller genomic deletion leading to Alport syndrome and mental retardation and we proposed to rename the contiguous gene syndrome ATS-MR.²³ Finally, we confirmed that the *FACL4* gene is indeed involved in MR through the identification of a missense mutation (p.R529S) in the FACS signature motif of the protein in MRX63, and of one splice site mutation in a family without linkage data.²⁰ Both these mutations abrogate the arachidonyl-CoA synthetase activity, and this abrogation might disturb an important developmental lipid associated cognitive process. The present study describes a third MRX family with a novel mutation in the *FACL4* gene and proposes a rapid and sensitive assay to screen for *FACL4* enzymatic activity in blood samples.

SUBJECTS AND METHODS

MRX68

The pedigree of family MRX68 (proband L46) includes five affected males, one of whom (II.5) died at 8 months of age. At

Table 1 Biometric measurements and cognitive levels in the MRX68 family

	Males				Females			
	Affected				Unaffected	Carrier	Non-carrier	
	II.6	II.7	III.2	III.3	II.1	II.3	II-8	III.1
Age, y	45	41	15	11	50	47	40	21
Height, cm (centile)	185 (90)	176 (25–50)	162.5 (25)	139 (50)	NA	158.0 (25)	159.0 (25)	169 (90)
Span, cm	188	183	NA	134	NA	167	167	168
Weight, kg (centile)	81 (90–97)	72 (75)	37.5 (3)	35 (50)	NA	96.0 (>>97)	62.0 (75)	82.0 (>97)
OFC, cm (centile)	55 (3)	54 (3)	NA	52 (50)	NA	52.5 (25)	53.0 (25)	55.5 (90–97)
ICD/OCD*, cm (centile)	3/10 (50/97)	3/9.5 (50/75–97)	NA	3/8.3 (50/50)	NA	2.8/10.0 (50/97)	3.2/9.5 (50–75/75–97)	3.5/9.5 (75–97/97)
H/F†, cm (centile)	20/8.5 (75–97/75–97)	19/8.5 (75–97/75–97)	NA	14/6 (3/3)	NA	18.0/7.5 (50–75/50)	17.5/7.0 (50/25)	17.5/7.5 (50/50)
Other	Varices	Varices	–	Autistic	–	Hypertension	–	–
FSIQ‡	NA	71	43	62	116	74	83	133
VIQ§	NA	71	47	61	113	71	83	131
PIQ¶	NA	74	47	66	118	84	86	128

*ICD/OCD=inner canthal distance/outer canthal distance, †H/F=hand/finger length, ‡FSIQ=full scale intelligence quotient, §VIQ=verbal intelligence quotient, ¶PIQ=performance intelligence quotient, NA=data not available.

the time of this study, four affected males (II.6, II.7, III.2, and III.3) were still alive, and all were available for clinical examination and blood sampling.

To determine the level of intelligence two domains were explored and included measurements of the mental level (including behaviour) and adaptive functioning.²⁴ To assess the mental level, cognitive strengths and weaknesses, the Wechsler Intelligence Scale for Children Revised (WISC-R)²⁵ was used in II.7 and III.3, and the Wechsler Adult Intelligence Scale (WAIS)²⁶ in II.1, II.3, II.8, III.1, and III.2. Behavioural observations were done with the “Child Behavior Check List (CBCL)” in III.3 in combination with the “Teacher’s Report Form (TRF)”. The “Youth Self Report (YSR)”²⁷ was obtained from III.2 and III.3. To measure the level of adaptive functioning, the “Assessment of Adaptive Areas (AAA)” was used.²⁸ The Dutch versions of all these tests and checklists were used.

All affected family members were subjected to physical examination, including biometric measurements, neurological, and clinical genetic investigations (table 1).

Other investigated families

In addition to family MRX68, we examined seven families showing linkage to large intervals of the X chromosome covering Xq22.3 collected by Leuven (probands L22, L49, L56) and by the Greenwood Genetic Center, South Carolina (families K8045, K8435, K8835, K8610).

Proband L22 belongs to family MRX35. The males have a non-specific condition with severe hyperkinetic behaviour and moderate mental retardation. Two point and multipoint linkage analysis with 18 highly polymorphic markers covering the entire X chromosome assigned the mutant locus to the Xq22-q26 region.²⁹

Probands L49 and L56 belong to two families with mental retardation and spastic paraplegia, mapping in Xp11.4-Xq24 (and Xq27-Xq28) and Xp11.3-Xq24, respectively (XLMR meeting, Strasbourg 1999 (L56) and Frascati 2001 (L49))³⁰.

Family K8435 has moderate mental retardation. Affected males have distinct facial features, hirsutism, seizures, unsteady gait, and slowly progressive weakness. Most affected males have hypogammaglobulinaemia with specific absence of plasma and/or secretory IgA.³¹ Two point linkage analysis, using 27 microsatellite markers on the X chromosome, places the mutant locus between Xq21.33 and Xq23.

All affected males of family K8045 had a normal facial appearance, moderate to severe MR and spastic paraplegia and they had never walked.³² A seven point linkage analysis yielded a maximum lod score for three loci spanning Xq22-q25.

In family K8610, males have agenesis/hypoplasia of the corpus callosum and features of FG syndrome.³³ Linkage analysis assigned the locus to Xq12-Xq22.3.

Family K8835 is unpublished. All affected males have significant developmental delay with variable phenotypic presentation. Macrocephaly, unusual gait, and macroorchidism are variously combined in the affected males of the family. Moreover, two of them have a prominent forehead and one has a round face. They are FRAXA negative. Linkage analysis placed the mutant locus on Xp11.3-Xq23.

Linkage analysis

Highly polymorphic microsatellite markers spread over the entire X chromosome were analysed on genomic DNA extracted from peripheral white blood cells of all family members. PCR amplification of these polymorphic markers was performed using fluorescein labelled locus specific primer pairs (Genome Database). Marker genotypes were determined by separation of PCR products on an ALF sequencer (Amersham Pharmacia Biotech). Sizing of the PCR products was done with the Allelelinks software (Amersham Pharmacia Biotech). Multipoint lod score analyses were performed using MLINK version 5.1³⁴ and FASTLINK version 2.2.³⁵ Map locations, genetic distances, and allele frequencies were obtained from the Genome Database (<http://gdbwww.gdb.org/>), the Location Database (<http://cedar.genetics.soton.ac.uk/pub/chromX/gmap>), Ensembl (<http://www.ensembl.org>), and Généthron data.³⁶ The mutation rate was set at 3×10^{-6} and gene frequency at 0.0001. For males, the penetrance was set at 0.0 and 1.0 for non-carriers and carriers of the disease gene, respectively. For females, the penetrance was set at 0.0 for non-carriers, 0.25 for heterozygous carriers, and 1.0 for homozygous carriers of the disease gene.

X inactivation studies and mutation analysis

X inactivation studies in all females, including female carriers of family MRX68 (I.2, II.3, and II.8), were performed using the previously described protocol³⁷ on DNA extracted from peripheral blood. Mutation analysis of the *FMRI* gene (the most common cause of XLMR) was performed using standard procedures.^{38–39} The *EACL4* coding region, encompassing exons 3–17 and covering both alternative start codons located in exons 3 and 4, respectively, was PCR amplified with specific primers.²⁰ Direct sequencing of PCR products was carried out in both directions with BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA) on an ABI 310 Automated Sequencer. Sequences were analysed with the Genescan package software.

Figure 1 Multipoint lod score analysis of family MRX68.

Figure 2 Chromatogram of mutated sequence. Sequence analysis showed a C>T transition at cDNA position 1001, changing a proline (CCG) into a leucine (CTG). Both the nucleotide and amino acid change are shown above the chromatogram. Intron bases are indicated in lower case letters. An arrow indicates the mutated nucleotide. Wt = wild type sequence. M = mutated sequence.

Segregation analysis in family MRX68 for the novel mutation identified in exon 10 was performed by *MspI* digestion of the PCR product of this exon (primers: F: 5'-AATCCAAGTGTAAGTCTG-3' and R: 5' TAAAAGGTCCAA GTACGATC-3'). The digest was analysed on a 1.5% agarose gel. Loss of the *MspI* site was confirmed by direct sequencing.

Enzymatic assay

To test FACL4 enzymatic activity in whole cell lysates obtained from EBV transformed cell lines, we have modified our origi-

Figure 3 Schematic representation of FACL4 brain specific isoform. The p.P375L substitution in MRX68 at the end of the first luciferase domain is indicated. The mutations previously found in other families are also shown. LR1 = luciferase domain 1, LR2 = luciferase domain 2, striped box = adenosine monophosphate binding motif, grey box = FACS consensus sequence, large circle = brain specific amino terminal peptide (41 amino acids). Zig zag line = truncation of the protein by the splice site mutation, c.1003-2 A>G. Small circles = missense mutations. Numbers at the top refer to the amino acid positions.

nal method²⁰ as follows: 10⁷ cells, instead of the original 10⁸, were harvested and resuspended in 200 µl of lysis buffer. Before proceeding with the test, 20 µl of the lysate were removed from each sample and used for protein quantification using the BIO-RAD protein assay (BIO-RAD). The remaining cell lysate was incubated for 20 minutes in 150 µl of a standard reaction mixture (100 mmol/l TRIS/HCl, pH 8.0, 6.67 mmol/l ATP, 0.66 mmol/l CoA, 5 mmol/l dithiothreitol, 20 mmol/l MgCl₂), and 40 µl of a solution containing arachidonic acid (50 mmol/l NaHCO₃, 7.5 mmol/l Triton X-100, 0.25 mmol/l arachidonic acid, corresponding to 10 nmol, and 2 × 10⁵ dpm of ¹⁴C labelled arachidonic acid). The reaction was stopped with 2.25 ml of 2-propanol:heptane:2 mol/l sulphuric acid (40:10:1), followed by 1.5 ml of heptane and 1 ml of water and vigorous shaking. After centrifugation (five minutes at 2000 rpm), the upper layer was removed and the lower aqueous phase was extracted three times with 2 ml of heptane. The

Figure 4 Segregation analysis. The DNA (*) of members of family MRX68 was analysed on an agarose gel after *MspI* (CCGG) digestion of the PCR product of *FACL4* exon 10. The site was lost in all affected males. A heterozygous loss of the site was observed in the obligate carrier females. M = molecular weight marker with sizes indicated on the right. A slash (/) indicates empty lines. H₂O = negative PCR control without DNA.

radioactivity in the upper (heptane) layers, containing arachidonic acid, and in the lower (aqueous) phase, containing arachidonyl-CoA, was determined by scintillation counting (Beckman). To determine enzyme activity, the total radioactivity (upper plus lower phase) and the percentage of this radioactivity in the lower phase were calculated. This percentage corresponds to the percentage of arachidonic acid used for the reaction (10 nmol) which has been converted to arachidonyl-CoA. The values were corrected for protein quantity. *FACL4* enzymatic activity was expressed as nmol of arachidonyl-CoA obtained per mg of total protein.

To perform the test in blood samples, 10 ml of blood was diluted with one volume of phosphate buffered saline (PBS) or physiological solution, mixed, and carefully layered on one volume of a solution containing Ficoll 99 g/l, sodium chloride 12 mmol/l, and sodium diatrizoate 0.16 mol/l. After centrifugation (2000 rpm for 40 minutes at room temperature), the upper layer of plasma and platelets was removed and the intermediate layer containing leucocytes was recovered into a fresh tube and washed twice with PBS or physiological solution. In order to eliminate the residual erythrocytes present after the treatment with Ficoll, the pellet of leucocytes was resuspended in 1 ml of water, incubated in ice for one minute, and then diluted to 10 ml with PBS or physiological solution and centrifuged at 2000 rpm for 10 minutes. Leucocytes were also isolated from blood samples conserved at room temperature for 24, 72, and 120 hours.

For cryopreservation, leucocytes were isolated from 10 ml of fresh blood using the Ficoll method as described above and then stored at -80°C until the test was performed. Both cryopreserved and room temperature conserved leucocytes were subjected to the enzymatic test using the protocol described above.

RESULTS

Molecular analysis

We have screened by direct sequencing the whole coding region of *FACL4* in eight X linked mental retardation families, two non-specific (MRX35 and MRX68), and six syndromic, mapping in a large region encompassing Xq22.3.²⁹⁻³¹⁻³³⁻⁴⁰ A *FACL4* pathogenic mutation was found in family MRX68. Multipoint linkage analysis, previously performed on this family using 25 highly polymorphic markers, indicated a candidate gene region of 12.5 cM between markers DXS8020

(Xq22.1) and DXS1220 (Xq23). A maximum lod score of 2.1 was obtained at markers DXS1153 and *COL4A5* (fig 1).

Mutation analysis of the *FACL4* gene in the family showed a missense mutation, c.1001C>T (brain isoform), which changes a highly conserved proline (CCG) at amino acid position 375 into a leucine (CTG) (figs 2 and 3). This resulted in the abrogation of a restriction site for *MspI*. Restriction analysis showed the presence of the mutation in all affected males and carrier females (fig 4). Sequence analysis confirmed the C>T transition in these people. The mutation was not found in 300 normal chromosomes.

The pedigree and clinical findings in the family are most compatible with the diagnosis of MRX (table 1). The affected males did not show facial dysmorphism or neurological abnormalities. An MRI scan of one affected subject was normal (data not shown). The neurocognitive levels ranged from mild (II.7) to moderate (III.2, III.3) MR in the affected males and the intelligence levels were borderline in female carriers (II.3, II.8) (table 1). The personality profile was analysed in three affected males (II.7, III.2, III.3) and all obtained poor results on the dimensions "motor activity" and "creativity". Internalising behavioural problems were observed in one subject (III.3), together with severe social problems, thought problems, and attention deficit. Autistic-like features were present in this child.

X inactivation studies in the obligate carrier females of the family (I.2, II.3, and II.8) showed 100% skewed inactivation profiles in all of them (data not shown).

Enzymatic assay

Analysis of the arachidonyl-CoA synthetase activity was performed on whole cell lysates obtained from both an EBV transformed cell line of an affected male (II.7) and leucocytes isolated from fresh blood of the same male. In both cases the analysis showed a marked reduction in activity in the patient with respect to normal controls (fig 5, columns 7 and 15). The reduction in activity was of the same extent as that observed in a male with *FACL4* deletion,²⁰ indicating that the p.P376L mutation strongly inhibits *FACL4* activity (fig 5, column 8).

In order to exclude *FACL4* intronic/promoter mutations, missed by coding sequence analysis, *FACL4* enzymatic activity was tested also in lymphoblastoid cell lines or leucocytes of each proband of the other seven families. No statistical differences were found in the arachidonyl-CoA synthetase activity between these probands (fig 5, columns 2-6 and 9-10) and controls.

Figure 5 Arachidonyl Co-A synthetase activity. The assay was carried out on whole cell lysates of 10^7 lymphoblastoid cell lines (columns 1-8) and of leucocytes isolated from 10 ml of blood samples (columns 9-15). For lymphoblastoid cell lines, results show the means of at least three independent experiments. Statistical evaluation between groups was done with Student's *t* test ($p=0.01$). Column 1 = normal control; 2 = L22; 3 = K8045; 4 = K8435; 5 = K8835; 6 = K8610; 7 = L46 (MRX68); 8 = male patient with genomic deletion (ATS-MR syndrome); 9 = L49; 10 = L56; 11 = control from 10 ml of blood after cryopreservation. Lanes 12-14 = controls after 24, 72, and 120 hours of blood preservation at room temperature; 15 = blood of L46 (MRX68) stored at room temperature for 24 hours. Columns 7, 8, and 15 (dark grey box) and column 14 (white box) were significantly different from controls.

Assessment of enzymatic assay on blood

When a disease gene encodes an enzyme expressed in leucocytes, a functional assay could be proposed not only to confirm a mutation but also to replace molecular analysis as a screening method. However, in our original description the method required the EBV transformation of B lymphocytes. This step is time consuming and expensive. With the aim of bypassing the cell transformation step and to apply the test directly to fresh blood, we have gradually reduced the number of cells used for the test from 10^8 to 10^7 . This number corresponds to the mean amount of leucocytes present in 10 ml of blood. Our analysis showed that 10^7 cells are enough to detect arachidonyl-CoA synthetase activity and to distinguish a *FACL4* mutation (fig 5, columns 1-8). In addition, enzymatic activities observed with 10^7 lymphoblastoid cells and with leucocytes isolated from 10 ml of blood are comparable both in patients and in controls (fig 5, columns 1-8 v 9-15). Moreover, we tested whether blood may be cryopreserved or stored at room temperature for several days before performing the analysis. Fig 5 shows that there is no difference in activity after cryopreservation (column 11) or after 24 or 72 hours of conservation at room temperature (columns 12-13). A significant reduction in activity ($p=0.01$) was noted after 120 hours at room temperature (fig 5, column 14).

DISCUSSION

We performed mutation analysis of the *FACL4* gene in family MRX68 and in seven other families that map in large regions encompassing Xq22.3. In MRX68 a novel mutation was identified that causes the substitution of a highly conserved proline with a leucine (p.P375L in brain isoform). The *FACL4* protein consists of two luciferase domains, the precise functions of which remain to be elucidated (fig 3). The conserved FACS signature motif, located in the second luciferase domain, is thought to be important for the binding of fatty acids and hence should play a crucial role in lipid metabolism. The recently reported missense mutation in MRX63 changes a conserved arginine within the FACS motif into a leucine, thereby interfering with the enzymatic activity.²⁰ In the same study, a mutation in intron 10, identified in another small family, uncovered a cryptic splice site that introduced a premature stop codon. This mutation is predicted to lead to a protein lacking the second luciferase domain

including the FACS signature motif. The new missense mutation presented here (p.P375L) is located at the end of the first luciferase domain that contains a putative AMP-binding signature motif. The mutated proline is highly conserved between all members of the *FACL* family including those of other species, and it can be hypothesised that sequence similarities presumably reflect functional requirements that are common to these enzymes. Therefore, this novel missense mutation is likely to be pathogenic since it cosegregates with the disease, strongly inhibits *FACL4* activity, involves a highly conserved residue, and was not found in 300 control chromosomes. Fatty acid binding assays and structural models of the wild type and mutant proteins will help to determine the precise function of the amino acids mutated in this and in the other families.

In the last few years, pathogenic mutations in the *MECP2*, *RPS6KA3*, and *ARX* genes have been identified in patients with both syndromic (MRXS) and non-specific (MRX) X linked mental retardation, indicating that the same gene can be responsible for both conditions.¹⁶⁻¹⁹ Given this, in addition to the two MRX families, we also analysed for *FACL4* mutations six MRXS families in which linkage analysis assigned the mutant locus to regions encompassing Xq22.3, suggesting a possible involvement of *FACL4*. No mutations were identified in these families, excluding the involvement of *FACL4* in their pathogenesis. However, given the small number of families tested, no conclusions regarding the role of *FACL4* in MRXS can be drawn. A larger panel of patients needs to be analysed in order firmly to establish whether *FACL4* is also involved in the onset of MRXS.

Long chain fatty acyl-CoA synthetases convert free fatty acids into fatty acyl-CoA esters, which are the key intermediates in the synthesis of complex cellular lipids (triglycerides, phospholipids, and cholesterol esters).⁴¹ The highly preferred substrates for *FACL4* include arachidonic acid (AA) and eicosapentaenoic acid (EPA).⁴² Compared to other tissues, brain tissue contains high amounts of polyunsaturated fatty acids (PUFAs), such as AA, EPA, and docosahexaenoic acids (DHA) in its membrane phospholipids. The central nervous system uses these PUFAs when cellular differentiation, active synaptogenesis, and photoreceptor membrane biogenesis takes place.⁴³ AA and DHA are the most abundant long chain PUFAs in brain, and influence membrane fluidity, recovery from injury, gene transcription, and signal transduction via protein kinase C, in a Ca^{2+} and diacylglycerol dependent way.⁴⁴⁻⁴⁷ Long chain acyl CoA esters have been reported to affect a large number of cellular processes including ion distribution, enzyme regulation, vesicle transport and membrane fusion, and gene expression.⁴⁸ This is particularly relevant when considering the possible effect of arachidonyl-CoA deficiency on neural development. Moreover, several randomised controlled studies show that long chain PUFAs do affect infant cognitive development, especially visual attention and problem solving.⁴³ Finally, it has been shown that EPA might prevent interleukin-1 β and radiation induced deterioration in rat neurones.⁴⁹⁻⁵⁰ Therefore, considerable reduction of the enzymatic activity of *FACL4* in the brain might lead to deranged fatty acid metabolism in neurones causing defects of neurone outgrowth, synaptogenesis, or other developmental restrictions important for normal brain development.

The functional assay of *FACL4* activity is a direct method to test whether the *FACL4* gene may be involved in a mentally retarded patient. We have modified the original enzymatic assay, which required EBV transformation of lymphocytes, into a simple test on blood and we propose this test for rapid screening of mentally retarded males. This enzymatic approach has a number of advantages over the standard molecular analysis and it is less laborious, much faster, and reagent intensive. On the basis of our experience, the operational cost of *FACL4* analysis by this enzymatic strategy is 75% lower than mutation analysis performed by either mutation screening methods or full sequencing. In addition to the

increased cost efficiency, the diagnostic enzymatic strategy has proven to be a sensitive and efficient method for *FACL4* investigation. Moreover, this approach allows the identification of functionally harmful intronic and promoter mutations that are usually missed by standard mutation analysis of coding sequences. Finally, by direct measurement of enzymatic activity, this method overcomes interpretation uncertainty commonly associated with missense changes. We showed that the test can be performed in blood conserved at room temperature up to 72 hours and thus can be applied to shipped samples from anywhere.

In conclusion, we describe a novel missense mutation in the *FACL4* gene in a family with non-specific mental retardation. The p.P375L mutation results in a big reduction of enzymatic activity, which might disturb cognition related brain lipid metabolism. Our data confirm the involvement of *FACL4* in MRX. Moreover, we developed a rapid enzymatic assay on peripheral blood which we propose as a sensitive, robust, and efficient diagnostic tool in mentally retarded males. This is the first biochemical assay that can be used to identify mutations in mentally retarded patients.

ACKNOWLEDGEMENTS

We thank the family members for their participation and assistance, Philippe Volcke and Lut van den Berghe, Connie Schrandt-Stumpel and Christine de Die for their expert clinical support, and Marianne Wouters for psychological testing. This work was supported by a Telethon grant (E.1145) to AR and in part by the Fund for Scientific Research of Flanders (Belgium) grant FWO-G0182.97 and G0229.01 (A5334).

Authors' affiliations

I Longo, I Meloni, C Pescucci, F Ariani, A Renieri, Medical Genetics, Department of Molecular Biology, University of Siena, Italy
S G M Frints, P Marynen, G Froyen, Human Genome Laboratory, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
J-P Fryns, M Borghgraef, Clinical Genetics Unit, University Hospital Leuven, Department of Human Genetics, Leuven, Belgium
M Raynaud, Service de Génétique, INSERM U316, Tours Cédex, France
C Schwartz, Greenwood Genetic Center, SC, USA

REFERENCES

- American Psychiatric Association.** *Diagnostic and statistical manual of mental disorders. DSM-IV.* Washington (DC): American Psychiatric Association, 1994.
- Neri G,** Chiurazzi P. X-linked mental retardation. *Adv Genet* 1999;**41**:55-94.
- Hagberg B,** Kyllerman M. Epidemiology of mental retardation - a Swedish survey. *Brain Dev* 1983;**5**:441-9.
- Turner G.** Finding genes on the X chromosome by which homo may have become sapiens. *Am J Hum Genet* 1996;**58**:1109-10.
- Turner G,** Turner B. X-linked mental retardation. *J Med Genet* 1974;**11**:109-13.
- Chelly J,** Mandel J. Monogenic causes of X-linked mental retardation. *Nat Rev Genet.* 2001;**2**:669-80.
- Gecz J,** Gedeon A, Sutherland G, Mulley J. Identification of the gene FMR2, associated with FRAXE mental retardation. *Nat Genet* 1996;**13**:105-8.
- Gu Y,** Shen Y, Gibbs R, Nelson D. Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. *Nat Genet* 1996;**13**:109-13.
- D'Adamo P,** Menegon A, Lo Nigro C, Grasso M, Gulisano M, Tamanini F, Bienvenu T, Gedeon A, Oostra B, Wu S, Tandon A, Valtorta F, Balch W, Chelly J, Toniolo D. Mutations in GDI1 are responsible for X-linked non-specific mental retardation. *Nat Genet* 1998;**19**:134-9.
- Zemni R,** Bienvenu T, Vinet M, Sefiani A, Carrie A, Billuau P, McDonell N, Couvert P, Francis F, Chafey P, Fauchereau F, Friocourt G, Portes V, Cardona A, Frints S, Meindl A, Brandau O, Ronce N, Moraine C, Bokhoven H, Ropers H, Sudbrak R, Kahn A, Fryns J, Beldjord C. A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation. *Nat Genet* 2000;**24**:167-70.
- Carrie A,** Jun L, Bienvenu T, Vinet M, McDonell N, Couvert P, Zemni R, Cardona A, Van Buggenhout G, Frints S, Hamel B, Moraine C, Ropers H, Strom T, Howell G, Whittaker A, Ross M, Kahn A, Fryns J, Beldjord C, Marynen P, Chelly J. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. *Nat Genet* 1999;**23**:25-31.
- Billuau P,** Bienvenu T, Ronce N, des Portes V, Vinet M, Zemni R, Roest Crolius H, Carrie A, Fauchereau F, Cherry M, Briault S, Hamel B, Fryns J, Beldjord C, Kahn A, Moraine C, Chelly J. Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. *Nature* 1998;**392**:923-6.
- Allen KM,** Gleeson JG, Bagrodia S, Partington MW, MacMillan JC, Cerione RA, Mulley JC, Walsh CA. PAK3 mutation in nonsyndromic X-linked mental retardation. *Nat Genet* 1998;**20**:25-30.
- Bienvenu T,** des Portes V, McDonell N, Carrie A, Zemni R, Couvert P, Ropers H, Moraine C, van Bokhoven H, Fryns J, Allen K, Walsh C, Boue J, Kahn A, Chelly J, Beldjord C. Missense mutation in PAK3, R67C, causes X-linked nonspecific mental retardation. *Am J Med Genet* 2000;**93**:294-8.
- Kutsche K,** Yntema H, Brandt A, Janke I, Nothwang H, Orth U, Boavida M, David D, Chelly J, Fryns J, Moraine C, Ropers H, Hamel B, van Bokhoven H, Gal A. Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho GTPases, in patients with X-linked mental retardation. *Nat Genet* 2000;**26**:247-50.
- Merienne K,** Jacquot S, Pannetier S, Zeniou M, Bankier A, Gecz J, Mandel JL, Mulley J, Sassone-Corsi P, Hanauer A. A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental retardation. *Nat Genet* 1999;**22**:13-14.
- Couvert P,** Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, Verloes A, Andres C, Le Fevre AC, Souville I, Steffann J, des Portes V, Ropers HH, Yntema HG, Fryns JP, Briault S, Chelly J, Cherif B. MECP2 is highly mutated in X-linked mental retardation. *Hum Mol Genet* 2001;**10**:941-6.
- Bienvenu T,** Poirier K, Friocourt G, Bahi N, Beaumont D, Fauchereau F, Ben Jeema L, Zemni R, Vinet M, Francis F, Couvert P, Gomot M, Moraine C, van Bokhoven H, Kalscheuer V, Frints S, Gecz J, Ohzaki K, Chaabouni H, Fryns J, Desportes V, Beldjord C, Chelly J. ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. *Hum Mol Genet* 2002;**11**:981-91.
- Stromme P,** Mangelsdorf M, Shaw M, Lower K, Lewis S, Bruyere H, Lutchera V, Gedeon A, Wallace R, Scheffer I, Turner G, Partington M, Frints S, Fryns J, Sutherland G, Mulley J, Gecz J. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. *Nat Genet* 2002;**30**:441-5.
- Meloni I,** Muscettola M, Raynaud M, Longo I, Bruttini M, Moizard M, Gomot M, Chelly J, des Portes V, Fryns J, Ropers H, Magi B, Bellan C, Volpi N, Yntema H, Lewis S, Schaffer J, Renieri A. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. *Nat Genet* 2002;**30**:436-40.
- Jonsson J,** Renieri A, Gallagher P, Kashtan CE, Cherniske EM, Bruttini M, Piccini M, Vitelli F, Ballabio B, Pober BR. Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis: a new X-linked contiguous gene deletion syndrome? *J Med Genet* 1998;**35**:273-8.
- Picini M,** Vitelli F, Bruttini M, Pober B, Jonsson JJ, Villanova M, Zollo M, Borsani G, Ballabio A, Renieri A. FACL4, a new gene encoding long chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis and mental retardation. *Genomics* 1998;**47**:350-8.
- Meloni I,** Vitelli F, Pucci L, Lowry B, Tonlorenzi R, Rossi E, Ventura M, Rizzoni G, Kashtan CE, Pober B, Renieri A. Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR). *J Med Genet* 2002;**39**:359-65.
- Borghgraef M,** Sacco S, Gomot M, De Vos B, Jacobs A, Buret V, Desportes V. Neuro-cognitive and behavioural aspects in non-specific mental retardation. A proposal for phenotyping new XLMR genes. *Genet Couns* 2002;**13**:195-8.
- Van Haasen P,** De Bruyn E, Pijl Y, Poortinga Y, Spelberg H, Vander Steene G, Coetsier P, Spoelers-Claes R, Stinissen J. *Wechsler Intelligence Scale for Children Revised (WISC-R): Handleiding, scoring en normen.* The Netherlands: Lisse, 1986.
- Stinissen J,** Willems PJ, Coetsier P, Hulsman WL. *Wechsler Adult Intelligence Scale (WAIS): Handleiding bij de Nederlandse bewerking.* The Netherlands: Lisse, 1970.
- Achenbach TM.** *Intergrative guide for the CBCL 4-18, YRS and TRF profiles.* Burlington, University of Vermont, Department of Psychiatry, 1991.
- Bryant B,** Taylor R, Pedrotty Rivera, D. *Assessment of adaptive areas. A method for obtaining scores that correspond to the American association on mental retardation's adaptive areas.* Examiner's manual. PRO-ED Inc, 1996:1-23.
- Gu XX,** Decorte R, Marynen P, Fryns JP, Cassiman JJ, Raemaekers P. Localisation of a new gene for non-specific mental retardation to Xq22-q26 (MRX35). *J Med Genet* 1996b;**33**:52-5.
- Raynaud M,** Ronce N, Moizard M, Briault S, Frints S, Yntema H, Des Portes V, Kalscheuer V, Chelly J, Moraine C. Extremely skewed X-inactivation profile in XLMR carriers in some families. *Genet Couns* 2002;**13**:244.
- Chudley AE,** Tackels DC, Lubs HA, Arena JF, Stoerber WP, Kovnats S, Stevenson RE, Schwartz CE. X-linked mental retardation syndrome with seizures, hypogammaglobulinemia, and progressive gait disturbance is regionally mapped between xq21.33 and Xq23. *Am J Med Genet* 1999;**85**:255-62.
- Arena J,** Schwartz C, Stevenson R, Lawrence I, Carpenter A, Duara R, Ledbetter D, Huang T, Lehner T, Ott J. Spastic paraplegia with iron deposits in the basal ganglia: a new X-linked mental retardation syndrome. *Am J Med Genet.* 1992;**43**:479-90.
- Graham J Jr,** Tackels D, Dibbern K, Superneau D, Rogers C, Corning K, Schwartz C. FG syndrome: report of three new families with linkage to Xq12-q22.1. *Am J Med Genet* 1998;**80**:145-56.
- Lathrop GM,** Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. *Proc Natl Acad Sci USA* 1984;**81**:3443-6.

- 35 **Cottingham R Jr**, Idury R, Schaffer A. Faster sequential genetic linkage computations. *Am J Hum Genet* 1993;**53**:252-63.
- 36 **Dib C**, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. *Nature* 1996;**380**:152-4.
- 37 **Raynaud M**, Moizard MP, Dessay B, Briault S, Toutain A, Gendrot C, Ronce N, Moraine C. Systematic analysis of X-inactivation in 19 XLMR families: extremely skewed profiles in carriers in three families. *Eur J Hum Genet* 2000;**8**:253-8.
- 38 **Brown T**, Tarleton J, Go R, Longshore J, Descartes M. Instability of the FMR2 trinucleotide repeat region associated with expanded FMR alleles. *Am J Med Genet*. 1997;**73**:447-55.
- 39 **Rousseau F**, Heitz D, Biancalana V, Blumenfeld S, Kretz C, Boue J, Tommerup N, Van Der Hagen C, DeLozier-Blanchet C, Croquette M. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. *N Engl J Med*. 1991;**325**:1673-81.
- 40 **Chiurazzi P**, Hamel BCJ, Neri G. XLMR genes: update 2000. *Eur J Hum Genet* 2001;**9**:71-81.
- 41 **Singh I**, Lazo O, Dhaunsi G, Contreras M. Transport of fatty acids into human and rat peroxisomes. *J Biol Chem* 1992;**1992**:13306-13.
- 42 **Cao Y**, Traer E, Zimmerman GA, McIntyre TM, Prescott SM. Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4). *Genomics* 1998;**49**:327-330.
- 43 **Willatts P**, Forsyth J. The role of long-chain polyunsaturated fatty acids in infant cognitive development. *Prostaglandins Leukot Essent Fatty Acids*. 2000;**63**:95-100.
- 44 **Bronfman M**, Morales MN, Orellana A. Diacylglycerol activation of protein kinase C is modulated by long chain acyl-CoA. *Biochem Biophys Res Commun* 1988;**159**:1026-31.
- 45 **de Urquiza AM**, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. *Science* 2000;**290**:2140-4.
- 46 **Horrocks L**. Phospholipids in nervous tissues. In: Eichberg J, ed. *Metabolism and function of fatty acids in brain*. New York: Wiley, 1985:173-99.
- 47 **Rapoport S**, Chang M, Spector A. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. *J Lipid Res* 2001;**42**:678-85.
- 48 **Faergeman NJ**, and Knudsen J. Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signaling. *Biochem J* 1997;**323**:1-12.
- 49 **Martin D**, Lonergan P, Boland B, Fogarty M, Brady M, Horrobin D, Campbell V, Ma L. Apoptotic changes in the aged brain are triggered by IL-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. *J Biol Chem* (in press).
- 50 **Lonergan P**, Martin D, Horrobin D, Ma L. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. *J Biol Chem* 2002;**277**:20804-11.

Want to know more?

Data supplements

Limited space in printed journals means that interesting data and other material are often edited out of articles; however, limitless cyberspace means that we can include this information online.
Look out for additional tables, references, illustrations.

www.jmedgenet.com